Julien Jerphanion

Scientific Open-Source Project Maintainer • Scientific Software Engineer @ QuantStack • MVA 2019—2020

📍 France🔄 Updated September 2026💼 2 investments📅 2 years investing🗓 Last invested Jun 2025
Angel investor🌍 France
2
Total investments
1
Early stage
1
Mid stage
0
Late stage
2y
Years active

Portfolio

2 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Individual Investor
Jun 2025
Ziwig Biotech is a biotechnology company pioneering the analysis of salivary RNA and the application of artificial intelligence to biomolecular biology. At the crossroads of medicine, data science, and digital technology, Ziwig develops non-invasive tests and therapeutic biomarkers designed to transform the diagnosis and management of chronic diseases—particularly those affecting women. Its flagship innovation, Endotest®, is the first non-invasive and highly reliable saliva-based test for the diagnosis of endometriosis. This breakthrough innovation, multiple award-winner (Galien Prize, Tech For Future Award), exemplifies Ziwig’s ability to revolutionize women’s health through the convergence of biotechnology, artificial intelligence, and precision medicine. Ziwig operates at the heart of a rapidly evolving global health ecosystem, where universal access to diagnosis and prevention is a major challenge for equity and sustainability. Through its scientific and societal commitment, Ziwig contributes to building a more human, accessible, and universal precision medicine—serving patients, healthcare professionals, and the health systems of the future. 🌐 www.ziwig.com
Individual Investor
Jul 2024
We are the company founded by the creators of scikit-learn. After standardizing how the world does machine learning, we’re now transforming the way enterprises practice data science.
Experience · 2 entries
All (2)
Investments (2)
2025
Individual Investor
Jun 2025
Ziwig Biotech is a biotechnology company pioneering the analysis of salivary RNA and the application of artificial intelligence to biomolecular biology. At the crossroads of medicine, data science, and digital technology, Ziwig develops non-invasive tests and therapeutic biomarkers designed to transform the diagnosis and management of chronic diseases—particularly those affecting women. Its flagship innovation, Endotest®, is the first non-invasive and highly reliable saliva-based test for the diagnosis of endometriosis. This breakthrough innovation, multiple award-winner (Galien Prize, Tech For Future Award), exemplifies Ziwig’s ability to revolutionize women’s health through the convergence of biotechnology, artificial intelligence, and precision medicine. Ziwig operates at the heart of a rapidly evolving global health ecosystem, where universal access to diagnosis and prevention is a major challenge for equity and sustainability. Through its scientific and societal commitment, Ziwig contributes to building a more human, accessible, and universal precision medicine—serving patients, healthcare professionals, and the health systems of the future. 🌐 www.ziwig.com
2024
Individual Investor
Jul 2024
We are the company founded by the creators of scikit-learn. After standardizing how the world does machine learning, we’re now transforming the way enterprises practice data science.